Cambridge, UK: Synoptics, a world leader in the development and manufacture
of innovative digital imaging systems for scientific applications, is delighted to
introduce its new Division, Synoptics Health (www.synopticshealth.com). This
Division will focus on imaging techniques within the clinical environment.
Synoptics has been successfully developing and supplying imaging solutions to
life science researchers across the globe since 1986. The new Synoptics Health
Division is currently utilising that expertise to provide a patented fluorescence
protein detection system, which has been developed over four years in partnership
with Queen Mary University of London (QMUL).
The rationale for commercialising this protein detection technology is that the
recent draft of the NHS CFPP-01-01 consultation document which offers guidance
on decontamination of reusable surgical instruments states that fluorescence
provides increased sensitivity and quantification of residual proteins on surgical instruments. Synoptics Health is therefore exploiting its technology in this field to
meet the needs of this consultation document.
Paul Ellwood, CEO of Synoptics Health stated: “Comments in the CFPP-01-01
consultation document indicate that fluorescence is the most sensitive method for
detection of proteins on surgical instruments. During the development of our
prototype system and reagents in collaboration with QMUL, we have achieved a
100-fold increase in the sensitivity of protein detection over current methods and
we are launching our first commercial fluorescence protein detection product at
Ellwood continued: “We feel the time is right for us to forge better links with decontamination professionals, which is why we have opened our new division.
Being able to talk to us at Synoptics Health will allow them to see how easily they
could implement our simple technology into their facility, secure in the knowledge they will be guided every step of the way. Using ultra sensitive testing will ensure
their decontamination processes are working efficiently and more importantly, will provide increased confidence that the surgical instruments they are sending out really are clean and safe.”
For Further Information Contact:
Jayne Arthur, Synoptics Health, Beacon House, Nuffield Road, Cambridge, CB4 1TF, UK.
Tel: +44(0) 1223-727114 Fax +44 (0) 1223-727101
Email: firstname.lastname@example.org Web site: www.synopticshealth.com
About Synoptics Health
Synoptics Health, based in Cambridge, UK is a new division of Synoptics, a world-leader in the development and manufacture of innovative digital imaging systems for a range of life science applications. The Company has three other divisions, Syngene, Syncroscopy and Synbiosis of which Syngene is the largest.
Syngene produces advanced systems for molecular biologists to analyse and document fluorescent DNA on gels and has systems in all the major pharmas and academic institutes world-wide. Synoptics’ other divisions Syncroscopy and Synbiosis specialise in digital imaging solutions for microscopy and microbial applications respectively. The Company founded in 1986, currently employs 45 people, 20 of whom are based at Synoptics Inc. in the USA.